BioMedWire Stocks

Study Finds That Exercise May Reduce Symptoms of Depression

New studies have found that exercising for 30 minutes may boost the benefits of therapy and decrease symptoms of depression for at least an hour and 15 minutes post workout. The studies were carried out by Iowa State University researchers, led by Professor Jacob Myer, who was also the lead author. The objective of the research was to find out how exercising influenced the symptoms of depression.

For their first study, the researchers recruited 30 adults who experienced major depressive episodes. Each participant was required to fill out surveys, which included the scales used to measure a number of cognitive tasks and symptoms of depression as well as standard questions. The participants filled out these surveys before, during and after a half-hour session of either sitting or moderate-intensity cycling and then again 25, 50 and 75 minutes post workout.

Using the data they gathered, the researchers tracked the changes in some characteristics of major depressive disorder, including reduced cognitive function, difficulty experiencing pleasure from previously enjoyable activities (anhedonia) and depressed mood state. They discovered that the depressed mood state of participants as well as anhedonia improved during the cycling exercise, noting that this was better than the levels of anhedonia of the participants who didn’t exercise.

The researchers then carried out another pilot study, which involved some of the participants exercising on their own either through walking, jogging or cycling for a half hour before they signed into their weekly virtual cognitive behavioral therapy session. Their exercise data was collected using Fitbit, with the researchers finding that the participants who exercised before their therapy sessions showed more improvements in the reduction of their depression symptoms.

The researchers also discovered that those who exercised before their therapy sessions had stronger and quicker connections with their therapists, which suggests that exercise may prime the brain to engage with work that may be more emotionally challenging. The researchers noted that these results demonstrated that exercise could help heighten the benefits of therapy for adults suffering from depression.

Meyer, who is a professor of kinesiology at the institution, stated that despite the small study population, the research had provided promising results on how exercise had some effect on depression. The researchers hope to conduct more research on the subject in the future in an effort to better understand how exercise can be used to help individuals suffering from chronic depression or be integrated into an effective treatment.

In the not-so-distant future, people diagnosed with depression could also benefit from the therapeutic effects of psychedelics, including psilocybin, if the R&D work being conducted by companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) bears fruit and receives regulatory approval.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat

A recent report from India is a stark reminder of ricin’s accessibility and the pressing…

11 hours ago

US House Passes Republican Healthcare Bill, ACA Extension Left Out

The U.S. House of Representatives passed a healthcare bill that didn’t include an extension of…

13 hours ago

Chronic Inflammation Could Be the Missing Key to Understanding Long Covid

In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human…

1 day ago

Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology

Research indicates that the advantages of nanoparticle delivery in pharma are significant Oncotelic Therapeutics has…

3 days ago

Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment

A new study done in India has produced results that bring into question the longstanding assumption that…

3 days ago

Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics

Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”)…

4 days ago